Contact
searchSearch
HMP Global

Multiple Sclerosis Topic Center

News
Industry Payments and Their Role in MS Drug Selection Among High-Volume Prescribers
08/28/2025
Juliet Gallagher
A recent observational study explored the prevalence of industry payments to neurologists who prescribe multiple sclerosis (MS) disease-modifying therapies (DMTs), uncovering significant associations between such payments and prescribing...
A recent observational study explored the prevalence of industry payments to neurologists who prescribe multiple sclerosis (MS) disease-modifying therapies (DMTs), uncovering significant associations between such payments and prescribing...
A recent observational study...
08/28/2025
First Report Managed Care
News
High-Efficacy Multiple Sclerosis Therapies Linked to Fewer Emergency Department Visits and Lower Risk
08/13/2025
Lisa Kuhns, PhD, MD
High-efficacy disease-modifying therapies (DMTs) for multiple sclerosis (MS) are linked to a reduced likelihood of emergency department (ED) visits, according to a study published in Neurology.
High-efficacy disease-modifying therapies (DMTs) for multiple sclerosis (MS) are linked to a reduced likelihood of emergency department (ED) visits, according to a study published in Neurology.
High-efficacy disease-modifying...
08/13/2025
First Report Managed Care
Conference Coverage
Exploring Patient Portal Messaging in MS Care: Value, Utilization, and Burnout Implications
06/03/2025
Juliet Gallagher
As patient portals become increasingly central to chronic disease management, new research presented at CMSC 2025 offers insights into how people living with multiple sclerosis (MS) use these tools—and how their adoption may intersect with...
As patient portals become increasingly central to chronic disease management, new research presented at CMSC 2025 offers insights into how people living with multiple sclerosis (MS) use these tools—and how their adoption may intersect with...
As patient portals become...
06/03/2025
First Report Managed Care
Conference Coverage
11-Year Data Support Sustained Efficacy and Safety of Ocrelizumab in MS
06/02/2025
Juliet Gallagher
At CMSC 2025, researchers presented 11-year follow-up data confirming the long-term efficacy and safety of ocrelizumab (OCR) in people with multiple sclerosis (pwMS), including both relapsing (pwRMS) and primary progressive (pwPPMS) forms of...
At CMSC 2025, researchers presented 11-year follow-up data confirming the long-term efficacy and safety of ocrelizumab (OCR) in people with multiple sclerosis (pwMS), including both relapsing (pwRMS) and primary progressive (pwPPMS) forms of...
At CMSC 2025, researchers...
06/02/2025
First Report Managed Care
Conference Coverage
Cladribine Tablets Show Strong Results in Patients With MS Switching from Injectable Therapies
05/29/2025
Grace Taylor, MS, MA
A real-world study found that cladribine tablets significantly reduce relapse rates and deliver high patient satisfaction in patients with relapsing multiple sclerosis switching from injectable therapies.
A real-world study found that cladribine tablets significantly reduce relapse rates and deliver high patient satisfaction in patients with relapsing multiple sclerosis switching from injectable therapies.
A real-world study found that...
05/29/2025
First Report Managed Care
Conference Coverage
Serum Biomarker Test May Track Disease Activity in Common MS Scenarios
05/28/2025
Hannah Musick
Multiple Sclerosis Disease Activity (MSDA) scores aligned with real-world multiple sclerosis scenarios, suggesting the test may help monitor disease activity and guide care between standard visits.
Multiple Sclerosis Disease Activity (MSDA) scores aligned with real-world multiple sclerosis scenarios, suggesting the test may help monitor disease activity and guide care between standard visits.
Multiple Sclerosis Disease...
05/28/2025
First Report Managed Care
Conference Coverage
DMT Exposure Tied to Greater Health Care Utilization, No Mobility Benefit in Matched Patients With MS
05/28/2025
Juliet Gallagher
New research presented at CMSC 2025 questions the long-term benefits of disease-modifying therapies (DMTs) in multiple sclerosis (MS), suggesting that these therapies may not improve mobility outcomes and could be associated with higher...
New research presented at CMSC 2025 questions the long-term benefits of disease-modifying therapies (DMTs) in multiple sclerosis (MS), suggesting that these therapies may not improve mobility outcomes and could be associated with higher...
New research presented at CMSC...
05/28/2025
First Report Managed Care
News
Achieving Equitable MS Outcomes Through Algorithmic Treatment Pathways
05/12/2025
Juliet Gallagher
Kaiser Permanente Southern California implemented the Multiple Sclerosis Treatment Optimization Program (MSTOP) in 2012 to address disparities in MS treatment outcomes among Black, Hispanic, and White patients.
Kaiser Permanente Southern California implemented the Multiple Sclerosis Treatment Optimization Program (MSTOP) in 2012 to address disparities in MS treatment outcomes among Black, Hispanic, and White patients.
Kaiser Permanente Southern...
05/12/2025
First Report Managed Care
News
MUSETTE Trial Confirms Optimal Dosing of Ocrelizumab for Relapsing MS
04/10/2025
Danielle Sposato
In a recent press release, Genentech has announced results from the phase 3 MUSETTE trial (NCT04544436), which evaluated higher doses of intravenous (IV) ocrelizumab (Ocrevus) in patients with relapsing multiple sclerosis (RMS).
In a recent press release, Genentech has announced results from the phase 3 MUSETTE trial (NCT04544436), which evaluated higher doses of intravenous (IV) ocrelizumab (Ocrevus) in patients with relapsing multiple sclerosis (RMS).
In a recent press release,...
04/10/2025
First Report Managed Care
News
Autoimmune Disease Impact on Health and Productivity of US Employees
03/26/2025
Grace Taylor, MS, MA
Chronic autoimmune conditions are emerging as a major, underrecognized burden on employers, driving up health care costs and disability claims across the US workforce.
Chronic autoimmune conditions are emerging as a major, underrecognized burden on employers, driving up health care costs and disability claims across the US workforce.
Chronic autoimmune conditions...
03/26/2025
First Report Managed Care
Industry Insights
News Conference Coverage
FRMC Volume 22, Issue 3

Current Issue

September 2025
Volume 22
Issue 3
Current Issue
Issue Archive

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use